drugset
drugset / Trial / NCT05053165

A Study to Assess the Safety and Tolerability of LB-P6 and LB-P8 in Healthy Participants

NCT05053165 ↗

Phase 1 Completed 31 enrolled LISCure Biosciences
RandomizedSequentialQuadruple-blindTreatment

Summary

The study is designed to assess the safety and tolerability of multiple ascending doses of LB-P6 or LB-P8 in healthy participants.

Timeline

Start
2022-01-04
Primary completion
2022-04-01
Completion
2022-06-29

Drugs

EvaluationDrugModalityDoseRoute
Subject LB-P6 Unknown — Oral
Subject LB-P8 Unknown — Oral

Indications

metabolic dysfunction-associated steatohepatitis rheumatoid arthritis